97. Ulcerative colitis
2,269 clinical trials,   1,331 drugs   (DrugBank: 241 drugs),   114 drug target genes,   181 drug target pathways

Searched query = "Ulcerative colitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
17 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000030988
2018/02/0101/02/2018Open-label, randomized, two-parallel-arm, single center study to designed to evaluate azathioprine versus adalimumab after induction of tacrolimus in refractory ulcerative colitis therapy Ulcerative ColitisInduce azathioprine and continue maintenance therapy by azathioprine
Induce adalimumab and continue maintenance therapy by adalimumab
Sakura Medical Center, Toho universityNULLPending15years-oldNot applicableMale and Female53Not applicableJapan
2NCT02954159
(ClinicalTrials.gov)
May 18, 201714/10/2016Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UCInduction of Response and Remission of Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in Patients With Moderately to Severely Active Ulcerative ColitisUlcerative ColitisDrug: Tacrolimus;Drug: Vedolizumab;Other: PlaceboMedical College of WisconsinTakedaTerminated18 Years65 YearsAll4Phase 3United States
3JPRN-UMIN000024936
2016/11/3022/11/2016Efficacy of additional Calcineurin inhibitors in anti TNF-alfa antibody refractory Ulcerative colitis Ulcerative colitispatients who received Infliximab continued to treat every 8 week and who received Adalimumab continued to treat every 2 week. Patients received Tacrolimus 0.5mg2Cap par day at day0. Day0 is day of first anti TNF-alfa antibody treat after participate this study. We control Tacrolimus trough levels 3 to 5 mg/ml.Keio University Gastroenterology and HepatologyNULLRecruiting16years-old150years-oldMale and Female30Not selectedJapan
4JPRN-UMIN000015912
2014/12/1515/12/2014Efficacy of maintenance therapy with adalimumab in ulcerative colitis achieving remission with tacrolimus ulcerative colitisTacrolimus will be decreased gradually three months after it was administered.
Adalimumab will be administrated three months after tacrolimus was administered, and tacrolimus will be decreased gradually.
Osaka Medical CollegeNULLRecruiting16years-old70years-oldMale and Female50Not applicableJapan
5JPRN-UMIN000013546
2014/06/0131/03/2014The effect ofgrepefruit juice on the patients with autoimmune diseases taking tacrolimus rheumatoid arthritis, lupus nephritis, polymyositis/dermatomyositis with interstitial pneumonia, ulcerative colitistake a glass of grapefruit juice every day
do not take grapefruit juice
Department of Rheumatology and Clinical Immunology, Kyoto University HospitalNULLPending16years-old80years-oldMale and Female20Not applicableJapan
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6JPRN-UMIN000013694
2014/05/1311/04/2014Individualized tacrolimus therapy for ulcerative colitis based on CYP3A5 SNPsIndividualized tacrolimus therapy for ulcerative colitis based on CYP3A5 SNPs - Tacrolimus therapy for ulcerative colitis based on CYP3A5 SNPs ulcerative colitisdetermine CYP3A5 SNP status
increase the initial dosage of tacrolimus
Kitasato University Kitasato Institute HospitalNULLComplete: follow-up complete18years-oldNot applicableMale and Female30Not selectedJapan
7JPRN-UMIN000013716
2014/04/1515/04/2014A study of infliximab administration method for tacrolimus-resistant active ulcerative colitis ulcerative colitisAfter administrating tacrolimus and infliximab for 6 weeks,tacrolimus is tapered to 0mg.
Infliximab monotherapy
Yokohama City University Medical CenterNULLComplete: follow-up complete16years-oldNot applicableMale and Female40Phase 2Japan
8JPRN-UMIN000004201
2013/12/0214/09/2010The evaluation of efficacy for remission maintenance with immunomodulator following remission induction with tacrolimus in patients with moderate to severe active refractory ulcerative colitis.:mucosal healing for prognosis The patients with moderate to severe active refractory ulcerative colitisGroup of remission maintenance therapy for 48 weeks with immunomodulator at from 2 to 4 weeks following remission induction with tacrolimus,
Group of no remission maintenance therapy with immunomodulator following remission induction with tacrolimus,
Osaka City University, Graduate School of Medicine,Department of GastroenterologyNULLComplete: follow-up complete16years-old65years-oldMale and Female50Not selectedJapan
9JPRN-UMIN000010776
2013/06/0101/06/2013An open label randomized controlled trial of tacrolimus versus cyclosporine treatment for severe ulcerative colitis Ulcerative colitistacrolimus (Prograf)
cyclosporine (Sandimmune)
Chiba University HospitalNULLRecruiting16years-old65years-oldMale and Female40Not selectedJapan
10JPRN-UMIN000010612
2013/05/0101/05/2013A comparative study of the efficacy of tacrolimus with infliximab in intractable ulcerative colitis Ulcerative colitisTacrolimus will be administered orally for 10 weeks at the trough level of 10-15 ng/ml for the first 2 weeks following that of 5-10 ng/ml for the rest of the study period.
Infliximab will be administered intravenously at the dose of 5 mg/kg at 0, 2, 6 weeks.
Department of Internal Medicine, Division of Gastroenterology and Hepatology, Keio University School of MedicineNULLComplete: follow-up complete20years-oldNot applicableMale and Female130Phase 4Japan
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT01418131
(ClinicalTrials.gov)
October 201215/8/2011Rectal Tacrolimus in the Treatment of Resistant Ulcerative ProctitisA Multi-centre Double Blind Randomised Placebo-controlled Study of the Use of Rectal Tacrolimus in the Treatment of Resistant Ulcerative ProctitisUlcerative ColitisDrug: Rectal tacrolimus;Drug: PlaceboThe University of Western AustraliaRoyal Brisbane and Women's Hospital;Royal Adelaide Hospital, Australia;Liverpool Hospital, Australia;Fremantle Hospital and Health ServiceCompleted18 YearsN/ABoth21Phase 4Australia
12JPRN-UMIN000005824
2011/07/0121/06/2011Examination of efficacy and safety of tacrolimus, immunomodulator for an outpatient with moderate to severe ulcerative colitis ulcerative colitisTacrolimus (12weeks)Juntendo UniversityNULLRecruiting16years-old65years-oldMale and Female20Not applicableJapan
13JPRN-UMIN000005033
2011/03/0101/03/2011Open-labeled prospective randomized study between tacrolimus only and tacrolimus with intensive (twice a week) GMA (granulocyte and monocyte absorptive apheresis) for ulcerative colitis ulcerative colitisPatients in tacrolimus only receive tacrolimus twice a day (at initial dose of 0.0025mg/kg, optimal serum traff level 10-15ng/ml (until 2 weeks) , 5-10ng/ml (after 2 weeks))
Patiens in tacrolimus with GMA receive tacrolimus twice a day and two GMA treatments per week.
Saitama Medical Center, Saitama Medical UniversityNULLComplete: follow-up complete12years-old75years-oldMale and Female50Not applicableJapan
14JPRN-UMIN000003785
2010/07/0101/07/2010Remission maintenance treatment of ulcerative colitis with tacrolimus in azathioprine-intolerant patients: a randomized comparative trial of 5-aminosalicylic acid (5-ASA) monotherapy versus 5-ASA and tacrolimus combination therapy. Ulcerative colitis5-aminosalicylic acid monotherapy arm:
5-aminosalicylic acid is administered to subjects during the study period (for 48 weeks).

5-aminosalicylic acid monotherapy and tacrolimus arm:
5-aminosalicylic acid is administered to subjects during the study period (for 48 weeks). Tacrolimus is administered to subjects for 12 weeks after the start of protocol treatment as a rule.
Department of Internal medicine, Division of Lower Gastroenterology, Hyogo College of MedicineNULLComplete: follow-up complete16years-old65years-oldMale and Female80Phase 3Japan
15JPRN-UMIN000003952
2010/07/0126/07/2010A multicenter, randomised, open-label study to evaluate the clinical efficacy and pharmacokinetics of oral tacrolimus (FK506) therapy under fasting and fed conditions in refractory ulcerative colitis ulcerative colitisFasting condition group: Tacrolimus ingestion 1 hour before meal
Fed condition group: Tacrolimus ingestion immediately following consumption of meal
Department of lower gastroenterology, Hyogo College of MedicineOsaka Medical CollegeOsaka City UniversityComplete: follow-up complete16years-oldNot applicableMale and Female40Phase 4Japan
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT00347048
(ClinicalTrials.gov)
September 200630/6/2006Tacrolimus (FK506) Study in Moderate to Severe Refractory Ulcerative Colitis PatientsTacrolimus (FK506) P-III Placebo-Controlled Double-Blind Study in Moderate to Severe Refractory Ulcerative Colitis PatientsUlcerative ColitisDrug: tacrolimus;Drug: PlaceboAstellas Pharma IncNULLCompleted16 Years64 YearsBoth62Phase 3Japan
17NCT00643071
(ClinicalTrials.gov)
September 200620/3/2008Tacrolimus (FK506) P-III, Open-label Study in Refractory Ulcerative Colitis PatientsTacrolimus (FK506) P-III, Open-label Study in Severe Refractory Ulcerative Colitis Patients or Patients Who Attended and Received Placebo in F506-CL-1107 StudyUlcerative ColitisDrug: TacrolimusAstellas Pharma IncNULLCompleted16 Years64 YearsBoth32Phase 3Japan